NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659


Metabolic Endocrine Education Foundation (MEEF)
638 Lindero Canyon Dr Suite # 380
Oak Park, CA 91377

Register Online: **www.heartindiabetes.com/registration**

CME Symposium

IN ASSOCIATION WITH THE 24th WCIRDC

EARN CME
ABIM-MOC
CREDITS
1.5



Recognizing Hypertrophic Cardiomyopathy in Patients with HFpEF

Friday, December 4, 2026
6:15 pm – 7:45 pm PST
Hilton Universal City Hotel
Los Angeles, California
DINNER WILL BE SERVED

All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from **Lexicon Pharmaceuticals**

Free for all 24th WCIRDC attendees. Register online: www.wcir.org/registration

This CME Symposium will be available FREE for ONE year.

JOINTLY PROVIDED TMIOA ABIM CME MOC ACCREDITED Creighton UNIVERSITY



RECOGNIZING HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS WITH HFPEF

CHAIRS: **Matthew J. Budoff, MD and Robert J. Chilton, DO**

6:15 pm – 7:45 pm	**Dinner CME Symposium Sierra Ballroom B**	**Supported by Lexicon Pharmaceuticals**
6:15 pm	**Introduction & Pre-CME Questions**	**Matthew J. Budoff, MD**
6:25 pm	**Differentiate HCM from Cardiometabolic HFpEF and Other Causes of LVH**	**Nihar R. Desai, MD, MPH**
6:45 pm	**Up to Date Diagnostic Modalities of HCM**	**Alejandro De Feria, MD**
7:05 pm	**Available and Emerging Treatment Options in HCM**	**Nosheen Reza, MD, MS**
7:25 pm	**Panel Discussion and Q&A: Future and Required Research to Impact Guidelines**	
	Panel: Matthew J. Budoff, MD; Alejandro De Feria, MD; Nihar R. Desai, MD, MPH; Nosheen Reza, MD, MS	
	Moderator: Robert J. Chilton, DO	
	Post-CME Questions & Concluding Remarks	
7:45 pm	**Adjourn**	

Program Description

Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiovascular disorders, yet it remains underrecognized and often misunderstood in clinical practice. Based on the 2026 ACC HFpEF Expert Consensus Decision Pathway, HCM-especially the nonobstructive form- is a cardiac HFpEF mimic that can be difficult to separate from idiopathic HFpEF or hypertensive heart disease. Affecting approximately 1 in 200–250 individuals, HCM presents with a wide spectrum of phenotypes—from asymptomatic carriers to patients with severe left ventricular outflow tract obstruction, arrhythmias, heart failure, or sudden cardiac death. Rapid advances in imaging, genetics, and therapeutics have transformed the diagnostic and therapeutic landscape, making ongoing clinician education essential.

This medical education symposium will address the relationship of HCM in patients with HFpEF. It will present UpToDate diagnostic modalities, available and developing treatments with a special focus on cardiac myosin inhibitors and the emerging role of SGLT 1/2i.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

- Recognize HCM as cause and mimic of HFpEF.
- Know diagnostic approaches including imaging and genetic testing.
- Be able to outline current and emerging treatment options.

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, internists, family physicians, and other primary care clinicians include advanced practice professionals interested in HCM and HF.

FACULTY



Matthew J. Budoff, MD, Chair
FACC, FAHA
Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology
Lundquist Institute, Harbor-UCLA Medical Center
Program Director of Cardiac CT
Division of Cardiology
Harbor-UCLA Medical Center
Torrance, California



Robert J. Chilton, DO, Chair
FACP, FACC, FAHA, MACOI, FASCAI
Professor of Medicine
Division of Cardiology
Associate Program Director
Interventional Cardiology
The University of Texas Health Science Center
San Antonio, Texas



Nihar R. Desai, MD, MPH
Associate Professor of Medicine
Yale School of Medicine
Vice Chief | Section of Cardiovascular Medicine
Investigator, Center For Outcomes
Research and Evaluation
New Haven, Connecticut



Alejandro De Feria, MD
Assistant Professor
Division of Cardiovascular Medicine
University of Pennsylvania
Associate Director of the
Center for Inherited Heart Disease
Philadelphia, Pennsylvania



Nosheen Reza, MD, MS
FACC, FHFSA, FAHA
Assistant Professor of Medicine
Penn Center for Inherited Cardiovascular Disease
Section of Advanced Heart Failure
Transplantation and Mechanical Support
Director, Penn Women in Cardiology Program
Division of Cardiovascular Medicine
Senior Fellow, Leonard Davis
Institute of Health Economics (Penn LDI)
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

CME DINNER SYMPOSIUM

This CME symposium is FREE for 24th WCIRDC attendees and will stay on-demand for 90 days.
This Symposium will be available FREE for ONE year following the meeting.
Learn more: WCIR.ORG/CMEsymposium

To register for the entire 24th WCIRDC meeting please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Creighton Health Sciences Continuing Education (HSCE) and Metabolic Endocrine Education Foundation (MEEF). Creighton Health Sciences Continuing Education (HSCE) is accredited by the ACCME to provide continuing medical education for physicians. Creighton Health Sciences Continuing Education (HSCE) designated this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent of their participation in the activity. For information please contact:
info@tmioa.com or 818 342 1889

This is a CME Program Supported by an Educational Grant from **Lexicon Pharmaceuticals**